|
WO2013096744A1
(en)
|
2011-12-21 |
2013-06-27 |
Novira Therapeutics, Inc. |
Hepatitis b antiviral agents
|
|
EA038942B1
(ru)
|
2012-08-28 |
2021-11-12 |
Янссен Сайенсиз Айрлэнд Юси |
Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
|
|
HUE034820T2
(en)
|
2013-02-28 |
2018-02-28 |
Janssen Sciences Ireland Uc |
Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
|
|
EA027068B1
(ru)
|
2013-04-03 |
2017-06-30 |
Янссен Сайенсиз Айрлэнд Юси |
Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
|
|
TWI651300B
(zh)
|
2013-05-17 |
2019-02-21 |
健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
EA035500B1
(ru)
|
2013-05-17 |
2020-06-25 |
Янссен Сайенсиз Айрлэнд Юси |
Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
|
|
DK3024819T3
(en)
|
2013-07-25 |
2018-06-06 |
Janssen Sciences Ireland Uc |
GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
|
|
KR102290189B1
(ko)
|
2013-10-23 |
2021-08-17 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
|
|
AU2014348518B2
(en)
|
2013-11-14 |
2019-01-03 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
JP6553059B2
(ja)
|
2014-02-05 |
2019-07-31 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
Ｈｂｖ感染の治療のための併用療法
|
|
WO2015118057A1
(en)
|
2014-02-06 |
2015-08-13 |
Janssen Sciences Ireland Uc |
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
EP3271019A1
(en)
|
2015-03-19 |
2018-01-24 |
Novira Therapeutics Inc. |
Azocane and azonane derivatives and methods of treating hepatitis b infections
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
HK1259410A1
(zh)
|
2015-09-29 |
2019-11-29 |
诺维拉治疗公司 |
乙型肝炎抗病毒剂的晶体形式
|
|
SG10202011827YA
(en)
|
2016-04-15 |
2021-01-28 |
Novira Therapeutics Inc |
Combinations and methods comprising a capsid assembly inhibitor
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
CN109414508A
(zh)
|
2016-05-27 |
2019-03-01 |
吉利德科学公司 |
使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
|
|
JP6935434B2
(ja)
*
|
2016-06-29 |
2021-09-15 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
オキサジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用
|
|
AU2017290755B2
(en)
*
|
2016-06-29 |
2021-07-01 |
Novira Therapeutics, Inc. |
Diazepinone derivatives and their use in the treatment of hepatitis B infections
|
|
CN109415368B
(zh)
*
|
2016-07-14 |
2021-04-30 |
豪夫迈·罗氏有限公司 |
用于治疗感染性疾病的羧基6,7-二氢-4H-吡唑并[1,5-a]吡嗪化合物
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
CN109923106B
(zh)
|
2016-09-02 |
2022-09-13 |
吉利德科学公司 |
toll样受体调节剂化合物
|
|
EP3507288B1
(en)
|
2016-09-02 |
2020-08-26 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
CN109790123B
(zh)
*
|
2016-09-18 |
2021-06-25 |
正大天晴药业集团股份有限公司 |
新型衣壳蛋白装配抑制剂
|
|
IL265921B2
(en)
|
2016-10-14 |
2024-05-01 |
Prec Biosciences Inc |
Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
|
|
TWI794190B
(zh)
|
2016-11-07 |
2023-03-01 |
加拿大商愛彼特生物製藥公司 |
含有取代的吡啶酮之三環化合物及其使用方法
|
|
TWI820984B
(zh)
|
2017-01-31 |
2023-11-01 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
DK3587420T3
(da)
*
|
2017-02-23 |
2021-06-07 |
Fujian Cosunter Pharmaceutical Co Ltd |
Tricyklisk forbindelse og anvendelser heraf
|
|
AU2018238138A1
(en)
|
2017-03-21 |
2019-10-17 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
WO2018227427A1
(en)
|
2017-06-14 |
2018-12-20 |
Bayer Aktiengesellschaft |
Substituted bridged diazepane derivatives and use thereof
|
|
EP4717317A2
(en)
|
2017-06-20 |
2026-04-01 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
GB201716871D0
(en)
*
|
2017-10-13 |
2017-11-29 |
Inst Of Cancer Research: Royal Cancer Hospital |
Compounds
|
|
JP2021501764A
(ja)
|
2017-11-02 |
2021-01-21 |
アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
Ｂ型肝炎ウイルス（ｈｂｖ）に対して有効な新規高活性アミノチアゾール置換インドール−２−カルボキサミド
|
|
MA50520A
(fr)
|
2017-11-02 |
2020-09-09 |
Aicuris Gmbh & Co Kg |
Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb)
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
US10966999B2
(en)
|
2017-12-20 |
2021-04-06 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
EA038176B9
(ru)
*
|
2018-01-04 |
2021-09-07 |
Фуцзянь Косантер Фармасьютикал Ко., Лтд. |
Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в
|
|
TWI707849B
(zh)
|
2018-02-13 |
2020-10-21 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
|
PL3759109T3
(pl)
|
2018-02-26 |
2024-03-04 |
Gilead Sciences, Inc. |
Podstawione związki pirolizyny jako inhibitory replikacji hbv
|
|
CA3090125A1
(en)
|
2018-03-14 |
2019-09-19 |
Janssen Sciences Ireland Unlimited Company |
Capsid assembly modulator dosing regimen
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
KR102591947B1
(ko)
|
2018-04-19 |
2023-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
EP3820572B1
(en)
|
2018-07-13 |
2023-08-16 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
TWI869058B
(zh)
|
2018-07-27 |
2025-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
TW202028190A
(zh)
*
|
2018-10-22 |
2020-08-01 |
美商艾森伯利生物科學公司 |
用於治療hbv之5員雜芳甲醯胺化合物
|
|
US11236085B2
(en)
|
2018-10-24 |
2022-02-01 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
TW202136261A
(zh)
|
2018-10-31 |
2021-10-01 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
TWI721623B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
PY1991608A
(es)
|
2018-11-02 |
2022-02-10 |
Aicuris Gmbh & Co Kg |
Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazina activas contra el virus de la hepatitis b (vhb)
|
|
PY1991603A
(es)
|
2018-11-02 |
2020-09-17 |
Aicuris Gmbh & Co Kg |
Nueva 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole -2-carboxamidas activas contra el virus de la hepatitis b (vhb)
|
|
UY38435A
(es)
|
2018-11-02 |
2020-05-29 |
Aicuris Gmbh & Co Kg |
Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
|
|
AU2019373679A1
(en)
|
2018-11-02 |
2021-05-27 |
Aicuris Gmbh & Co. Kg |
Novel urea 6,7-dihydro-4H-thiazolo(5,4-c)pyridines active against the hepatitis B virus (HBV)
|
|
AR116946A1
(es)
|
2018-11-02 |
2021-06-30 |
Aicuris Gmbh & Co Kg |
Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
|
|
AR117189A1
(es)
|
2018-11-02 |
2021-07-21 |
Aicuris Gmbh & Co Kg |
Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
MX2021010145A
(es)
|
2019-02-22 |
2021-09-14 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
|
|
EP3935066A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
KR102707808B1
(ko)
|
2019-03-07 |
2024-09-19 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
SG11202111493WA
(en)
|
2019-04-30 |
2021-11-29 |
Aicuris Gmbh & Co Kg |
Novel oxalyl piperazines active against the hepatitis b virus (hbv)
|
|
PH12021552749A1
(en)
|
2019-04-30 |
2022-07-11 |
Aicuris Gmbh & Co Kg |
Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
|
|
SG11202111236UA
(en)
|
2019-04-30 |
2021-11-29 |
Aicuris Gmbh & Co Kg |
Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
|
|
PH12021552733A1
(en)
|
2019-04-30 |
2023-01-16 |
Aicuris Gmbh & Co Kg |
Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
|
|
MA55879A
(fr)
|
2019-05-06 |
2022-03-16 |
Janssen Sciences Ireland Unlimited Co |
Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
CR20210687A
(es)
|
2019-06-25 |
2022-03-03 |
Gilead Sciences Inc |
PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
CN119770638A
(zh)
|
2019-09-30 |
2025-04-08 |
吉利德科学公司 |
Hbv疫苗和治疗hbv的方法
|
|
US12410418B2
(en)
|
2019-12-06 |
2025-09-09 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
US11718637B2
(en)
|
2020-03-20 |
2023-08-08 |
Gilead Sciences, Inc. |
Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same
|
|
US20210371388A1
(en)
*
|
2020-05-12 |
2021-12-02 |
Baruch S. Blumberg Institute |
Bicyclic Carboxamide with Exocyclic Urea Derivatives as Antivirals for the Treatment of HBV Infection
|
|
US12569500B2
(en)
|
2020-05-15 |
2026-03-10 |
Fujian Akeylink Biotechnology Co., Ltd. |
Combination comprising tricycle compound and use thereof in preparation of medicament for treating HBV
|
|
PE20230779A1
(es)
|
2020-08-07 |
2023-05-09 |
Gilead Sciences Inc |
Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
EP4337223A1
(en)
|
2021-05-13 |
2024-03-20 |
Gilead Sciences, Inc. |
Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
|
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345389A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|